BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers worldwide. We use our expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. Our flagship product, The NGAL Test™, aids in the risk assessment of acute kidney injury (AKI) in critically ill patients. Designed to run on standard chemistry analyzers, it is CE marked and pending FDA 510(k) clearance. BioPorto is headquartered in Denmark, with US headquarters in Chicago, and is listed on NASDAQ Copenhagen.